As PRC counsel to the issuer, Han Kun Law Offices represented Adlai Nortye Ltd. ("Adlai Nortye", NASDAQ: ANL) in relation to the initial public offering of its American depositary shares in the United States and the listing of its American depositary shares on the Nasdaq Global Market.
Adlai Nortye is a global clinical-stage biotechnology company with global R&D and clinical operations centers established in China and United States, building a number of global product pipelines with a mode of "joint innovation" and "independent research and development"